Projects In Knowledge: Osteoporosis: A Focus on Fracture Prevention

Osteoporosis: A Focus on Fracture Prevention
>An On-Demand Webcast

PLEASE NOTE:

As required by the ACCME, all participants must read the information below before proceeding to this activity.

After doing so, please click the View Webcast button at the bottom of this page.

Although current osteoporosis therapies are effective in reducing the risk of fracture and increasing bone mineral density, all have some issues that limit their use. The gastrointestinal side effects of oral bisphosphonates may preclude their use in some patients, while agents requiring intravenous or subcutaneous administration may pose problems with compliance for others. Recent advances in understanding bone remodeling and the pathophysiology of osteoporosis have led to the identification of novel therapeutic targets and the development of new emerging agents. In this program, three experts in the field – Dolores M. Shoback, MD, Paul D. Miller, MD, and E. Michael Lewiecki, MD – discuss these important advances and their implications for the treatment of patients at risk of fracture and bone loss.

Chair
	E. Michael Lewiecki, MD, FACP, FACE Osteoporosis Director New Mexico Clinical Research & Osteoporosis Center Clinical Assistant Professor of Medicine University of New Mexico School of Medicine Albuquerque, New Mexico
Faculty
	Paul D. Miller, MD Distinguished Clinical Professor of Medicine University of Colorado Medical Center Colorado Center for Bone Research Lakewood, Colorado	Dolores M. Shoback, MD Professor of Medicine Department of Medicine University of California San Francisco VA Medical Center San Francisco, California

Target Audience
This activity is designed for internists, primary care physicians, family practitioners, endocrinologists, gynecologists, orthopedic surgeons, rheumatologists, nurses, and other clinicians involved in the care of patients with or at risk of developing osteoporosis and fractures.

Activity Goal
The goal of this CME/CE activity is to address gaps in competence and practice performance by:

Stressing the importance of early screening and diagnosis of patients with or at risk for developing osteoporosis and fractures
Identifying the pathways involved in the pathophysiology of osteoporosis and fractures
Providing optimal strategies for prevention and treatment of osteoporosis based on updates on current and emerging therapies with regard to mechanism of action, efficacy, safety, and treatment regimen requirements for compliance

top

Learning Objectives

•	Assess the mechanisms of action of approved and emerging osteoporosis agents, based on an understanding of bone remodeling and the pathophysiology of osteoporosis, in determining the role of these agents in preventing fractures and improving bone mineral density/bone quality in patients at risk of bone loss/fractures.
•	Based on clinical efficacy and safety data, dosing regimens, and route of administration of approved osteoporosis agents, individualize fracture prevention and osteoporosis treatment regimens that improve bone health and facilitate compliance.
•	Analyze the potential roles of emerging anabolic, antiresorptive, and dual-action therapies based on their safety and efficacy in preventing fractures/improving bone health when planning future regimens for use when these agents become available.

top

CME Information: Physicians
Statement of Accreditation
Projects In Knowledge^® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Projects In Knowledge designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CE Information: Nurses
Projects In Knowledge^® (PIK) is an approved provider of continuing nursing education by the Delaware Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. PIK provider code: 080903-PROV.

Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.

This activity is approved for 1.00 nursing contact hour(s).

DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any commercial product or service.

DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any commercial product or service.

CE Information: Pharmacists

Projects In Knowledge^® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This webcast is worth up to 1.00 contact hour (0.1 CEU). The ACPE Universal Program Number assigned to this application activity is 0052-0000-09-092-H01-P.
top

Disclosure Information
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

E. Michael Lewiecki, MD, FACP, FACE, has received grant/research support from Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Procter & Gamble, Hoffmann-La Roche Inc, sanofi-aventis, and Wyeth; is on the speakers bureau of Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; is on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, Novartis Pharmaceuticals Corporation, Upsher-Smith Laboratories Inc, and Wyeth; is a direct stock shareholder with General Electric, Procter & Gamble, and Teva Pharmaceuticals; and is on the board of directors of International Society for Clinical Densitometry. Dr. Lewiecki will be discussing the off-label/investigational uses of bazedoxifene, denosumab, lasofoxifene, odanacatib, sclerostin monoclonal antibody, and strontium ranelate.

Paul D. Miller, MD, has received grant/research support from Amgen Inc, Eli Lilly and Company, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis; and is a consultant for and/or on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, NPS Pharmaceuticals Inc, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis. Dr. Miller will be discussing the off-label/investigational uses of clodronate, etidronate, pamidronate, and strontium ranelate.

Dolores M. Shoback, MD, is a consultant for Amgen Inc, and GlaxoSmithKline; and has received honoraria from GlaxoSmithKline and Kai Pharmaceuticals. Dr. Shoback will be discussing the off-label/investigational use of sclerostin monoclonal antibody.

Karen Gravelle, PhD, has disclosed no significant relationships.

Projects In Knowledge’s staff members have no significant relationships to disclose.

top

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Contract for Mutual Responsibility in CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here.

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

	View Webcast Requires Flash 8 or higher and high-speed internet
top	1885